Global Gallstone Market to Reach USD 648.75 Million by 2032 | CAGR of 7.8%
Category : Pharmaceuticals | Published Date : Jan 2025 | Type : Press Release
Gallstone Market Scope & Overview:
As per the Consegic Business Intelligence newly published report, the Gallstone Market size was valued at USD 355.75 million in 2024 and is projected to grow at a CAGR of 7.8%, reaching USD 648.75 million by 2032. Gallstones are solid deposits that form in the gallbladder due to imbalances in bile substances such as cholesterol and bilirubin. They vary in size and composition, often causing symptoms like pain, nausea, and digestive issues. Treatment options include medications, non-invasive procedures, and surgical interventions to alleviate symptoms and prevent complications.
The report comprises the Gallstone Market Share, Size & Industry Analysis, based on Type (Cholesterol Gallstones, Pigment Gallstones, Mixed Gallstones), Cause (Cholesterol Stone, Bilirubin, Concentrated Bile, Others), Diagnosis (Ultrasound, Imaging Tests, Endoscopic Retrograde Cholangiopancreatography (ERCP), Blood Tests, Others), Treatment (Open Cholecystectomy, Laparoscopic Cholecystectomy, Extracorporeal Shock Wave Lithotripsy (ESWL), Medications, Others), End-User (Hospitals, Ambulatory Surgical Centers, Specialty Clinics), and Region (North America, Europe, Asia-Pacific, Latin America, Middle East & Africa), and Forecast, 2025-2032.
The report contains detailed information on Gallstone Market Trends, Opportunities, Value, Growth Rate, Segmentation, Geographical Coverage, Company Profiles, In-depth Expert Analysis, Revenue Forecast, Competitive Landscape, Growth Factors, Restraints or Challenges, Environment & Regulatory Landscape, PESTLE Analysis, PORTER Analysis, Key Technology Landscape, Value Chain Analysis, and Cost Analysis.
The rising prevalence of obesity and sedentary lifestyles significantly drives the market, while side effects associated with gallstone medications pose a challenge.
Segmental Analysis :
Based on type, the market is segmented into Cholesterol Gallstones, Pigment Gallstones, and Mixed Gallstones.
- The cholesterol gallstones segment held the largest revenue share of 61.30% in 2023, driven by their prevalence in obesity-related cases and high-fat dietary habits. These stones are effectively diagnosed via imaging techniques like ultrasound and CT scans.
- The mixed gallstones segment is anticipated to register the fastest CAGR during the forecast period, supported by advancements in diagnostic technologies and increasing cases of health conditions like cirrhosis and sickle cell anemia.
Based on cause, the market is segmented into Cholesterol Stone, Bilirubin, Concentrated Bile, and Others.
- The cholesterol stone segment accounted for the largest revenue in 2023, attributed to its high prevalence among patients with unhealthy dietary habits and sedentary lifestyles.
- The bilirubin segment is expected to grow rapidly, driven by rising cases of chronic conditions like liver cirrhosis and hemolytic diseases.
Based on diagnosis, the market is segmented into Ultrasound, Imaging Tests, Endoscopic Retrograde Cholangiopancreatography (ERCP), Blood Tests, and Others.
- The ultrasound segment dominated the market in 2023 due to its non-invasive nature, cost-effectiveness, and high accuracy.
- The imaging tests segment is projected to grow at the fastest rate, fueled by the adoption of advanced imaging technologies like CT and MRI for complex cases.
Based on treatment, the market is segmented into Open Cholecystectomy, Laparoscopic Cholecystectomy, Extracorporeal Shock Wave Lithotripsy (ESWL), Medications, and Others.
- The laparoscopic cholecystectomy segment held the largest revenue share in 2023, supported by its minimally invasive nature and shorter recovery times.
- The ESWL segment is expected to grow rapidly due to its non-invasive approach to breaking gallstones using shock waves.
Based on regions, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and Latin America.
- North America: Held the largest market share of USD 118.01 million in 2024, driven by advanced healthcare infrastructure and high obesity rates.
- Asia-Pacific: Anticipated to register the fastest growth with a CAGR of 8.3%, supported by urbanization, dietary shifts, and improved healthcare access in countries like China and India.
| Report Attributes | Report Details |
| Study Timeline | 2019-2032 |
| Market Size in 2032 | USD 648.75 Million |
| CAGR (2025-2032) | 7.8% |
| Type | Cholesterol Gallstones, Pigment Gallstones, Mixed Gallstones |
| Cause | Cholesterol Stone, Bilirubin, Concentrated Bile, Others |
| Diagnosis | Ultrasound, Imaging Tests, Endoscopic Retrograde Cholangiopancreatography (ERCP), Blood Tests, Others |
| Treatment | Open Cholecystectomy, Laparoscopic Cholecystectomy, Extracorporeal Shock Wave Lithotripsy (ESWL), Medications, Others |
| End-User | Hospitals, Ambulatory Surgical Centers, Specialty Clinics |
| By Region | North America(U.S., Canada, Mexico) Europe(U.K., Germany, France, Spain, Italy, Russia, Benelux, Rest of Europe) APAC(China, South Korea, Japan, India, Australia, ASEAN, Rest of Asia-Pacific) Middle East & Africa(GCC, Turkey, South Africa, Rest of MEA) LATAM(Brazil, Argentina, Chile, Rest of LATAM) |
Top Key Players & Competitive Landscape :
The competitive landscape encompasses major innovators, aftermarket service providers, industry giants, and niche players, all of which are thoroughly examined by Consegic Business Intelligence in terms of their strengths, weaknesses, and value-addition potential. This report includes detailed profiles of key players, market share analysis, mergers and acquisitions, resulting market fragmentation, and emerging partnership trends and dynamics.
List of prominent players in the Gallstone Industry:
- AbbVie Inc. (United States)
- AstraZeneca PLC (United Kingdom)
- Bristol-Myers Squibb Company (United States)
- Johnson & Johnson (United States)
- Novartis AG (Switzerland)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Pfizer Inc. (United States)
- Mylan N.V. (United States)
- GSK PLC (United Kingdom)
- Sun Pharmaceutical Industries Ltd. (India)
Recent Industry Developments :
- 2024: Pfizer launched an advanced bile acid formulation aimed at improving gallstone treatment efficacy.
- 2023: Novartis collaborated with gastroenterologists to innovate non-invasive gallstone treatment techniques.
